| Metric | FY 2026 | FY 2025 |
|---|---|---|
| Revenue | 459.4 | 376.6 |
| Profit before tax | -129.8 | -77.0 |
| Net income | -130.2 | -77.7 |
| EPS (diluted, $ a share) | $-2.08 | $-1.30 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +22.0% |
|---|---|
| Operating margin | -30.4% |
10-K filed with the SEC, NASDAQ: TWST. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Twist Bioscience Corp: key numbers
- Share price
- $105.04Close, Nov 16
- Market cap
- $7.16B
- Shares outstanding
- 68.18MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Twist Bioscience Corp
All →Twist Bioscience Financial Results
Twist Bioscience reported record fiscal 2026 revenue of $459.4 million, a 22% increase year-over-year, driven by strong growth in DNA Synthesis and NGS Applications. The company achieved positive adjusted EBITDA in the fourth quarter and improved its annual gross margin to 52.4%. Management issued fiscal 2027 revenue guidance of $550 million to $560 million, representing approximately 21% growth at the midpoint.
- Term
- FY2026
“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet.”
Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience
“We enter fiscal 2027 with a stronger business and the capital to invest in our next phase of growth. AI is expanding what scientists can design, and personalized medicine is increasing the demand for unique molecules. Both play directly to our strength of customization at scale.”
Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience
Twist Bioscience Insider Dennis Cho Sells $128K of Stock
Dennis Cho sold 949 shares of Twist Bioscience Corp at $135.40 a share, worth $128K in total on Nov 3, 2026. Shares held after the trade: 62,840 (-1.5%).
- Value
- $128K
- Shares
- 949
- Price
- $135.40
- Holding change
- -1.5%
- Trade date
- Nov 3, 2026
Twist Bioscience SVP of Human Resources Paula Green Sells $136K of Stock
Paula Green, SVP of Human Resources, sold 1,007 shares of Twist Bioscience Corp at $135.40 a share, worth $136K in total on Nov 3, 2026. Shares held after the trade: 105,625 (-0.9%).
- Value
- $136K
- Shares
- 1,007
- Price
- $135.40
- Role
- SVP of Human Resources
- Holding change
- -0.9%
- Trade date
- Nov 3, 2026
Twist Bioscience CEO Emily M. Leproust Sells $619K of Stock
Emily M. Leproust, CEO, sold 4,573 shares of Twist Bioscience Corp at $135.40 a share, worth $619K in total on Nov 3, 2026. Shares held after the trade: 558,187 (-0.8%).
- Value
- $619K
- Shares
- 4,573
- Price
- $135.40
- Role
- CEO
- Holding change
- -0.8%
- Trade date
- Nov 3, 2026
Twist Bioscience CAO Robert F. Werner Sells $20K of Stock
Robert F. Werner, CAO, sold 148 shares of Twist Bioscience Corp at $135.40 a share, worth $20K in total on Nov 3, 2026. Shares held after the trade: 42,769 (-0.3%).
- Value
- $20K
- Shares
- 148
- Price
- $135.40
- Role
- CAO
- Holding change
- -0.3%
- Trade date
- Nov 3, 2026
Twist Bioscience President and COO Patrick John Finn Sells $347K of Stock
Patrick John Finn, President and COO, sold 2,565 shares of Twist Bioscience Corp at $135.40 a share, worth $347K in total on Nov 3, 2026. Shares held after the trade: 180,278 (-1.4%).
- Value
- $347K
- Shares
- 2,565
- Price
- $135.40
- Role
- President and COO
- Holding change
- -1.4%
- Trade date
- Nov 3, 2026